Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BCL2A1 | Q16548 | 2/20 | 0.39 |
| ▸ | NR3C1 | P04150 | 1/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 5/20 | 0.36 |
| ▸ | TYK2 | P29597 | 2/20 | 0.36 |
| ▸ | TP53 | P04637 | 4/20 | 0.36 |
| ▸ | GAA | P10253 | 1/20 | 0.36 |
| ▸ | MEN1 | O00255 | 2/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.36 |
| ▸ | KLK1 | P06870 | 1/20 | 0.35 |
| ▸ | MAPT | P10636 | 2/20 | 0.35 |
| ▸ | ACHE | P22303 | 1/20 | 0.35 |
| ▸ | PDE1B | Q01064 | 2/20 | 0.35 |
| ▸ | NPC1 | O15118 | 2/20 | 0.35 |
| ▸ | RAB9A | P51151 | 2/20 | 0.35 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
| ▸ | HPGD | P15428 | 1/20 | 0.35 |
| ▸ | HTT | P42858 | 1/20 | 0.35 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3017547 | 0.93 | BCL2A1 (0.40) | BCL2A1NR3C1SMN1; SMN2TP53GAA | |
| SCHEMBL24263381 | 0.86 | PDE1B (0.39) | NR3C1SMN1; SMN2MEN1KMT2APDE1B | |
| SCHEMBL13422031 | 0.86 | SMN1; SMN2 (0.36) | BCL2A1NR3C1SMN1; SMN2TP53GAA | |
| SCHEMBL3022661 | 0.85 | DHODH (0.42) | NR3C1SMN1; SMN2TYK2MEN1KMT2A | |
| SCHEMBL3025027 | 0.84 | PDE1B (0.37) | BCL2A1NR3C1SMN1; SMN2TP53GAA | |
| SCHEMBL3024933 | 0.84 | TP53 (0.36) | BCL2A1NR3C1SMN1; SMN2TP53GAA | |
| SCHEMBL3717107 | 0.83 | NR3C1 (0.39) | NR3C1MEN1KMT2AMAPTALDH1A1 | |
| SCHEMBL20504495 | 0.82 | PDE1B (0.38) | TYK2MEN1KMT2APDE1B | |
| SCHEMBL2358823 | 0.81 | NR1D1 (0.36) | BCL2A1NR3C1SMN1; SMN2TP53GAA | |
| SCHEMBL3026837 | 0.81 | TYK2 (0.47) | TYK2PDE4D |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1928879-B1 | FUSED HETEROCYCLIC COMPOUNDS USEFUL AS KINASE MODULATORS | BRISTOL MYERS SQUIBB CO (US) | 2013-02-13 | — | — | EP | disclosed |
| US-20100204212-A1 | FUSED HETEROCYCLIC COMPOUNDS USEFUL AS KINASE MODULATORS | BRISTOL-MYERS SQUIBB COMPANY | 2010-08-12 | — | — | US | disclosed |
| US-7723336-B2 | Fused heterocyclic compounds useful as kinase modulators | BRISTOL-MYERS SQUIBB COMPANY (US) | 2010-05-25 | — | — | US | disclosed |
| US-20080045536-A1 | FUSED HETEROCYCLIC COMPOUNDS USEFUL AS KINASE MODULATORS | BRISTOL-MYERS SQUIBB COMPANY | 2008-02-21 | — | — | US | disclosed |
| US-20070078136-A1 | Fused heterocyclic compounds useful as kinase modulators | BRISTOL-MYERS SQUIBB COMPANY | 2007-04-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070078136-A1 | Fused heterocyclic compounds useful as kinase modulators | MAP3K2, MAP3K3, MAP4K2 | BCL2A1 2699/4885NR3C1 750/4885SMN1; SMN2 3786/4885 |
| US-20100204212-A1 | FUSED HETEROCYCLIC COMPOUNDS USEFUL AS KINASE MODULATORS | MAP2K2, MAP3K2, MAP4K2 | BCL2A1 1776/4885NR3C1 697/4885SMN1; SMN2 4011/4885 |
| US-20080045536-A1 | FUSED HETEROCYCLIC COMPOUNDS USEFUL AS KINASE MODULATORS | MAP3K3, MAP3K2, MAP4K3 | BCL2A1 1883/4885NR3C1 544/4885SMN1; SMN2 4020/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.